Status:
TERMINATED
Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients
Lead Sponsor:
Montefiore Medical Center
Conditions:
Secondary Hyperparathyroidism
Hypercalcemia
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Secondary hyperparathyroidism can persist following successful renal transplantation and can cause high blood calcium, kidney dysfunction or failure and excessive bone loss among other problems. If th...
Detailed Description
Secondary Hyperparathyroidism in the renal transplant recipient can cause abnormal bone and mineral metabolism, resulting in hypercalcemia that is detrimental to renal function, causing renal dysfunct...
Eligibility Criteria
Inclusion
- Renal transplant recipient at least 3 months post transplant
- Hypercalcemic, with serum calcium \> 10.5 milliequivalents per liter (mEq/L)
- Persistent hyperparathyroidism, with inappropriately elevated parathyroid hormone (PTH)
Exclusion
- Allergic to Cinacalcet HCl, tetracycline
- Pregnant
- On medication that utilizes same liver system as Cinacalcet HCl
Key Trial Info
Start Date :
February 9 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00415584
Start Date
February 9 2007
End Date
November 1 2009
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montefiore Medical Center
The Bronx, New York, United States, 10467